SEC Company Response from Alaunos Therapeutics, Inc. (TCRT) (CIK 0001107421) (TCRT) — Sep 2, 2022
Alaunos Therapeutics, Inc. (TCRT) (CIK 0001107421)
Date: Sept. 2, 2022 · CIK: 0001107421 · Accession: 0001193125-22-237887
AI Filing Summary & Sentiment
File numbers found in text: 333-266841
Letter
ALAUNOS THERAPEUTICS, INC.
8030 El Rio Street
Houston, TX
September 2, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Alaunos Therapeutics, Inc.
Registration Statement on Form S-3
Initially filed August 12, 2022
File No. 333-266841
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Alaunos Therapeutics, Inc. (the “Company”) hereby requests that the effective date for the registration statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on Wednesday, September 7, 2022, or as soon as practicable thereafter.
Should you have any questions or comments regarding the foregoing, please call the Company’s counsel, Brian K. Rosenzweig, who can be reached at (212) 841-1108, or Lilit Kazangyan, who can be reached at (424) 332-4769, of Covington & Burling LLP.
Very truly yours,
Alaunos Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP ALAUNOS THERAPEUTICS, INC. 8030 El Rio Street Houston, TX 77054 September 2, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Alaunos Therapeutics, Inc. Registration Statement on Form S-3 Initially filed August 12, 2022 File No. 333-266841 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Alaunos Therapeutics, Inc. (the “Company”) hereby requests that the effective date for the registration statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on Wednesday, September 7, 2022, or as soon as practicable thereafter. Should you have any questions or comments regarding the foregoing, please call the Company’s counsel, Brian K. Rosenzweig, who can be reached at (212) 841-1108, or Lilit Kazangyan, who can be reached at (424) 332-4769, of Covington & Burling LLP. Very truly yours, Alaunos Therapeutics, Inc. By: /s/ Melinda Lackey Name: Melinda Lackey Title: Senior Vice President, Legal